SCHEMBL10007433

SCHEMBL10007433

CN(CCc1ccc(Cl)cc1)C(=O)n1c(=O)n(C)c2nc(Cc3ccccc3)ncc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.40
▸ TRPV1 Q8NER1 1/20 0.38
▸ MGLL Q99685 1/20 0.38
▸ MAOB P27338 3/20 0.38
▸ ALDH1A1 P00352 4/20 0.37
▸ NPSR1 Q6W5P4 3/20 0.37
▸ TP53 P04637 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ USP1 O94782 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ TLR7 Q9NYK1 1/20 0.35
▸ MAOA P21397 2/20 0.35
▸ LIPE Q05469 1/20 0.35
▸ HTT P42858 2/20 0.35
▸ NOS3 P29474 1/20 0.34
▸ NOS1 P29475 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10007579 0.88 TLR7 (0.40) FAAHMAOBALDH1A1USP1POLB
SCHEMBL10006762 0.86 TLR7 (0.39) MAOBMAPTUSP1TLR7MAOA
SCHEMBL10006688 0.85 TLR7 (0.38) FAAHMAOBUSP1POLBRAB9A
SCHEMBL10006781 0.85 TSPO (0.40) MAOBALDH1A1SMN1; SMN2MAOA
SCHEMBL10006474 0.83 MEN1 (0.38) FAAHMAOBMAPTUSP1NPC1
SCHEMBL10006463 0.80 MEN1 (0.36) FAAHMAOBTP53MAPTUSP1
SCHEMBL10006640 0.80 USP1 (0.40) MAOBUSP1TLR7MAOA
SCHEMBL10006643 0.80 USP1 (0.40) ALDH1A1MAPTUSP1CYP1A2
SCHEMBL10292527 0.79 MAOB (0.36) MAOBALDH1A1NPSR1TP53MAPT
SCHEMBL10006851 0.78 TRPV1 (0.36) TRPV1MGLLMAOBALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 — — EP claimed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US claimed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 — — EP claimed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US claimed
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 — — EP disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 — — EP disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE FAAH, FAAH2, TPMT FAAH 1/4885TRPV1 619/4885MGLL 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback